dennisdave
3 minutes ago
Following the approval of Moderna's RSV vaccine on February 28, 2025 , the MHRA granted marketing authorization for lazertinib on March 6, 2025 , and approved Trofolastat for prostate cancer imaging on March 28, 2025 . Therefore, the MHRA has continued its regular approval activities beyond February